Latest Epidermal growth factor receptor Stories
Patients with ALK-rearranged non-small cell lung cancer (NSCLC) responded significantly better to pemetrexed (brand name: Alimta) than patients whose cancer did not show ALK translocation.
GERMANTOWN, Maryland and HILDEN, Germany, August 16, 2011 /PRNewswire/ -- - Diagnostic-therapeutic combination aims to improve standard of care for patients with non-small cell lung cancer (NSCLC) - Molecular test for KRAS gene mutations holds potential to help determine whether there is a subset of patients who are more likely to benefit from Pfizer's investigational anticancer compound - Collaboration in lung cancer...
WALTHAM, Mass., June 27, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that data from two entinostat clinical trials both based on tumor reprogramming will be presented at the International Association for the Study of Lung Cancer's (IASLC) 14th World Conference on Lung Cancer meeting (www.2011worldlungcancer.org) July 3 to 7 in Amsterdam, The Netherlands.
BOULDER, Colo., and PLEASANTON, Calif., June 2, 2011 /PRNewswire/ -- Clovis Oncology, Inc. and Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that they have entered into an agreement to develop an in vitro PCR (Polymerase Chain Reaction) based companion diagnostic test.
Asian non-small cell lung cancer (NSCLC) patients survive longer than Caucasians no matter how many drugs are given in a first-line setting, and the effect was apparent both before and after the introduction of targeted therapies in the early 2000s.
OMAHA, Neb., May 26, 2011 /PRNewswire/ -- Transgenomic, Inc.
RIDGEFIELD, Conn., May 25 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
Some of the most effective and expensive cancer drugs, dubbed "smart drugs" for their ability to stop tumors by targeting key drivers of cancer cell growth, are not effective in some patients.
Two sets of gene expression profiles predict response to a common lung cancer drug for patients that have no guiding indicators for their treatment now.
A detailed analysis of lung tumors that became resistant to targeted therapy drugs has revealed two previously unreported resistance mechanisms.
- A volcanic mudflow.